Sorafenib

Title	Average Rating
A phase II study of sorafenib in combination with tegafur/uracil (UFT) for Asian patients with advanced hepatocellular carcinoma	80.00%
Phase II trial of pharmacodynamically (PDally)-guided optimal biologic dose titration (OBDT) of sorafenib (S) in combination wit	70.00%
Sorafenib and radiation: A promising combination in colorectal and pancreas cancer	70.00%
Metastatic chest wall malignant schwannoma responding to sorafenib: case report and literature review.	70.00%
Clinical management of adrenocortical carcinoma	60.00%
A phase II clinical trial of sorafenib in androgen-independent prostate cancer.	60.00%
Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase path--	60.00%
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.	50.00%
Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors.	50.00%
Tumoral angiogenesis: review of the literature.	50.00%
Bioavailability of sorafenib tablets administered as a liquid suspension.	30.00%

Languages